Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Shares Outstanding (Weighted Average): 2012-2024

Historic Shares Outstanding (Weighted Average) for Adma Biologics (ADMA) over the last 10 years, with Dec 2024 value amounting to $236.4 million.

  • Adma Biologics' Shares Outstanding (Weighted Average) rose 2.38% to $238.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.6 million, marking a year-over-year increase of 2.38%. This contributed to the annual value of $236.4 million for FY2024, which is 4.61% up from last year.
  • Latest data reveals that Adma Biologics reported Shares Outstanding (Weighted Average) of $236.4 million as of FY2024, which was up 4.61% from $226.0 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Shares Outstanding (Weighted Average) ranged from a high of $236.4 million in FY2024 and a low of $94.5 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $219.7 million, with a median of $226.0 million in 2023.
  • Data for Adma Biologics' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 107.11% (in 2021) over the last 5 years.
  • Over the past 5 years, Adma Biologics' Shares Outstanding (Weighted Average) (Yearly) stood at $94.5 million in 2020, then surged by 107.11% to $195.8 million in 2021, then increased by 0.49% to $196.8 million in 2022, then climbed by 14.83% to $226.0 million in 2023, then climbed by 4.61% to $236.4 million in 2024.